Evolving role of uPA/uPAR system in human cancers
Top Cited Papers
- 3 January 2008
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 34 (2), 122-136
- https://doi.org/10.1016/j.ctrv.2007.10.005
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- PAI-1 −675 4G/5G polymorphism as a prognostic biomarker in breast cancerBreast Cancer Research and Treatment, 2007
- Identification of uPAR-positive Chemoresistant Cells in Small Cell Lung CancerPLOS ONE, 2007
- uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s viewThrombosis and Haemostasis, 2007
- Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 ExpressionCancer Epidemiology, Biomarkers & Prevention, 2006
- Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family historyThe Prostate, 2006
- RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in VivoJournal of Biological Chemistry, 2005
- Cancer chemoprevention with dietary phytochemicalsNature Reviews Cancer, 2003
- Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell CarcinomaThe American Journal of Pathology, 2000
- Mitogenic Effects of Urokinase on Melanoma Cells Are Independent of High Affinity Binding to the Urokinase ReceptorPublished by Elsevier BV ,1998
- Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.JCI Insight, 1995